Skip to main navigation

Our Company
Medicines
- OJEMDA™
Our Pipeline
Join Our Team
Investors & Media
Patients, Families & Advocates

Select Page

Investors & Media

Events & Presentations

Investors & Media

Events & Presentations

Presentations

View All

Corporate Presentation - April 2024

Upcoming Events

View All

Please check back for upcoming events.

Past Events

View All

Apr 24, 2024
8:30 AM EDT

OJEMDA™ FDA Approval Call

Supporting Materials

OJEMDA FDA Approval Call Presentation 7.1 MB

Mar 05, 2024
9:50 AM EST

TD Cowen 44th Annual Health Care Conference

Jun 04, 2023
6:00 PM CDT

Day One Conference Call

Supporting Materials

ASCO 2023 Conference Call Presentation 2.3 MB

Jun 13, 2022
8:00 AM EDT

Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma

Supporting Materials

Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma 2.6 MB

Investor Contact

Investor Relations
investors@dayonebio.com

Media Contact

Laura Cooper
Media@dayonebio.com

Helpful Tools

Print Page
Email Alerts
RSS Feed

Our Company

Mission & Strategy
Leadership
Partnering
Contact

Medicines

OJEMDA™

Our Pipeline

Development Overview
Tovorafenib
Pimasertib
Clinical Trials
Expanded Access
Presentations & Posters
Investigator-Sponsored Research

Join Our Team

Career Opportunities
Our Culture
Diversity & Inclusion
Benefits that Matter

Investors & Media

Company Overview
Press Releases
Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

Patients, Families & Advocates
News for the Community
Our Patient Advocacy

© 2024 Day One Biopharmaceuticals, Inc.

Privacy Policy
Terms of Use